Correction to: J Exp Clin Cancer Res 36, 115 (2017)
https://doi.org/10.1186/s13046-017-0585-2
Anzeige
Following publication of the original article [1], the authors identified some minor errors in image-typesetting in Figs. 2 and 3; specifically in Fig. 2b, and Fig. 3a and d.
Fig. 2
Combined treatment of J-4 and Celecoxib synergistically inhibited the invasion of melanoma cells. a and b The invasion of B16-F10 (a) and A375 (b) cells was significantly inhibited by a 24-h treatment of the combination of J-4 (25 μM) and Celecoxib (25 μM) assessed via Transwell assay. c and d The dose-effect curve and CI of the synergistic effect of J-4 with Celecoxib in A375 (c) and B16-F10 (d) cells calculated by the CalcuSyn software 2.1. * P < 0.05; ** P < 0.0
Fig. 3
The combination of J-4 and Celecoxib significantly inhibited the migration of melanoma cells. a and b Wound healing assay results in B16-F10 cells with various treatments for 3, 6, 9, 12, and 24 h. c and d Wound healing assay results in A375 cells with various treatments for 3, 6, 9, 12, and 24 h. The migration distance was measured by a software-based method. J-4: 25 μM; Celecoxib: 25 μM. * P < 0.05; ** P < 0.01
×
×
In Fig. 2b, the picture of cell invasion assay in J-4 group has been corrected.
In Fig. 3a, the picture of wound healing assay in J-4 group (24 h) has been corrected.
In Fig. 3d, the pictures of wound healing assay in Celecoxib group (0 h) has been corrected.
Anzeige
The corrected figures are given below. The corrections do not have any effect on the final conclusions of the paper.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
